Utibron Neohaler FDA Approval History
Last updated by Judith Stewart, BPharm on May 3, 2020.
FDA Approved: Yes (Discontinued) (First approved October 29, 2015)
Brand name: Utibron Neohaler
Generic name: glycopyrrolate and indacaterol
Dosage form: Inhalation Powder
Company: Novartis Pharmaceuticals Corporation
Treatment for: COPD
Utibron Neohaler (glycopyrrolate and indacaterol) is a long-acting muscarinic antagonist (LAMA) and long-acting beta2-adrenergic agonist (LABA) fixed-dose combination for the long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).
Development timeline for Utibron Neohaler
| Date | Article |
|---|---|
| Oct 29, 2015 | Approval FDA Approves Utibron Neohaler (indacaterol/glycopyrrolate) for COPD |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
